CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For client-friendly information
on navicular syndrome and lameness exams please refer to www.equinelameness.com. As with all drugs, side effects may
occur. In feld studies, the most common side effects reported were signs of discomfort or nervousness, cramping, pawing,
and/or colic within 2 hours post-treatment. Osphos should not be used in pregnant or lactating mares, or mares intended
for breeding. Use of Osphos in patients with conditions affecting renal function or mineral or electrolyte homeostasis is not
recommended. Refer to the prescribing information for complete details or visit www.dechra-us.com.
For Technical Support or information, contact:
Dechra Veterinary Products at
866-933-2472
www.dechra-us.com
www.osphos.com
Navicular syndrome is a multifaceted disease and the
treatment options are not always clear. When radiographic
signs indicative of bony changes associated with navicular
syndrome are present, O
sphos is a clear choice. Osphos is
a bisphosphonate designed for convenient IM administration.
O
sphos inhibits bone resorption by binding to calcium
phosphate crystals (inhibiting their formation and d issolution),
and by exerting direct cellular effects on osteoclasts.
The Choice is Clear
The Only Intramuscular Option
for Control of Clinical Signs
Associated with Navicular Syndrome
Convenient intramuscular injection
Effcacious — 56 days after administration 74.7%
of horses had decreased lameness scores
Ready to use solution — one vial treats one horse
FDA approved for control of clinical signs
associated with navicular syndrome in horses
FDA approved for repeat administration (at 3-6
month intervals) to maintain clinical improvement